Current Report Filing (8-k)
May 15 2019 - 4:44PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (date of earliest event reported):
May 15, 2019
AgeX
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
1-38519
|
|
82-1436829
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File Number)
|
|
Identification
No.)
|
1010
Atlantic Avenue
Suite
102
Alameda,
California 94501
(Address
of principal executive offices)
(510)
871-4190
(Registrant’s
telephone number, including area code)
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol
|
|
Name
of exchange on which registered
|
Common
Stock, par value $0.0001 per share
|
|
AGE
|
|
NYSE
American
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Forward-Looking
Statements
Any
statements that are not historical fact (including, but not limited to statements that contain words such as “may, “will,”
“believes,” “plans,” “intends,” “anticipates,” “expects,” “estimates”)
should also be considered to be forward-looking statements. Additional factors that could cause actual results to differ materially
from the results anticipated in these forward-looking statements are contained in AgeX’s periodic reports filed with the
SEC under the heading “Risk Factors” and other filings that AgeX may make with the Securities and Exchange Commission.
Undue reliance should not be placed on these forward-looking statements which speak only as of the date they are made, and the
facts and assumptions underlying these statements may change. Except as required by law, AgeX disclaims any intent or obligation
to update these forward-looking statements.
References
in this Report to “AgeX,” “we” or “us” refer to AgeX Therapeutics, Inc.
The
information in Item 2.02 and the accompanying Exhibit 99.1 shall be deemed “furnished” and not “filed”
under Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to
the liability of that section, and shall not be incorporated by reference into any filings made by AgeX under the Securities Act
of 1933, as amended, or the Exchange Act except as may be expressly set forth by specific reference in such filing.
Item
2.02 - Results of Operations and Financial Condition
On
May 15, 2019, AgeX issued a press release announcing its financial results for the three months ended March 31, 2019. A copy of
the press release is attached as Exhibit 99.1, which, in its entirety, is incorporated herein by reference.
Item
9.01 - Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AGEX
THERAPEUTICS, INC.
|
|
|
|
Date:
May 15, 2019
|
By
|
/s/
Russell Skibsted
|
|
|
Chief
Financial Officer
|
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Aug 2024 to Sep 2024
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Sep 2023 to Sep 2024